Tobira Therapeutics Company Profile (NASDAQ:TBRA)

About Tobira Therapeutics

Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBRA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.86
  • 50 Day Moving Average: $6.62
  • 200 Day Moving Average: $8.24
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.93
  • P/E Growth: 0.04
  • Market Cap: $91.47M
  • Outstanding Shares: 18,821,000
  • Beta: -0.48
Additional Links:
Companies Related to Tobira Therapeutics:

Analyst Ratings

Consensus Ratings for Tobira Therapeutics (NASDAQ:TBRA) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.75 (306.38% upside)

Analysts' Ratings History for Tobira Therapeutics (NASDAQ:TBRA)
Show:
DateFirmActionRatingPrice TargetDetails
8/13/2016HC WainwrightReiterated RatingBuy$22.00 -> $31.00View Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details
7/25/2016Cantor FitzgeraldDowngradeBuy$19.00View Rating Details
5/10/2016Leerink SwannReiterated RatingBuy$18.00View Rating Details
2/22/2015WedbushReiterated RatingUnderperform$1.00View Rating Details
11/6/2014Jefferies GroupReiterated RatingHold$1.50 -> $1.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Tobira Therapeutics (NASDAQ:TBRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/9/2016Q216($0.63)($0.71)$1.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.53)($0.65)ViewN/AView Earnings Details
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details
8/11/2015Q215($0.99)ViewListenView Earnings Details
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tobira Therapeutics (NASDAQ:TBRA)
Current Year EPS Consensus Estimate: $-2.65 EPS
Next Year EPS Consensus Estimate: $-2.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.69)($0.69)($0.69)
Q4 20161($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tobira Therapeutics (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tobira Therapeutics (NASDAQ:TBRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2016A/S NovoMajor ShareholderSell59,067$12.02$709,985.34View SEC Filing  
7/7/2016A/S NovoMajor ShareholderSell92,119$12.20$1,123,851.80View SEC Filing  
6/30/2016A/S NovoMajor ShareholderSell66,814$13.04$871,254.56View SEC Filing  
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.00View SEC Filing  
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.00View SEC Filing  
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.00View SEC Filing  
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.00View SEC Filing  
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.00View SEC Filing  
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tobira Therapeutics (NASDAQ:TBRA)
DateHeadline
investornewswire.com logoWill Tobira Therapeutics, Inc. (NASDAQ:TBRA) Hit $31 Price Target? - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - August 18 at 10:47 AM
News IconBiotech news that matter for investors: Tobira Therapeutics, Inc. (TBRA), Celldex Therapeutics, Inc. (CLDX) - The Voice Registrar (NASDAQ:TBRA)
voiceregistrar.com - August 16 at 11:01 AM
investing.com logoTobira Therapeutics Inc Broke Out Of A Bottom Pattern (NASDAQ:TBRA)
www.investing.com - August 15 at 9:51 AM
News IconInvestor News: Tobira Therapeutics Inc (NASDAQ:TBRA) faces Investigation over possible Violations of Securities Laws (NASDAQ:TBRA)
www.groundreport.com - August 15 at 9:50 AM
News IconAnalysts Review on Trending Stock: Tobira Therapeutics Inc (NASDAQ:TBRA) - Post Registrar (NASDAQ:TBRA)
postregistrar.com - August 13 at 10:31 AM
News IconAnalysts Review: Tobira Therapeutics, Inc. (NASDAQ:TBRA) | | Post ... - Post Registrar (NASDAQ:TBRA)
postregistrar.com - August 11 at 8:17 PM
News IconTobira Reports Second Quarter 2016 Financial And Business Results (NASDAQ:TBRA)
www.biospace.com - August 10 at 8:15 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tobira Therapeutics, Inc. (TBRA) (NASDAQ:TBRA)
finance.yahoo.com - August 10 at 10:52 AM
sg.finance.yahoo.com logoTobira reports 2Q loss (NASDAQ:TBRA)
sg.finance.yahoo.com - August 9 at 8:01 PM
biz.yahoo.com logoTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:TBRA)
biz.yahoo.com - August 9 at 8:01 PM
biz.yahoo.com logoTOBIRA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:TBRA)
biz.yahoo.com - August 9 at 8:01 PM
publicnow.com logoTobira Therapeutics Reports Second Quarter 2016 Financial and Business Results (NASDAQ:TBRA)
www.publicnow.com - August 9 at 8:01 PM
biz.yahoo.com logoQ2 2016 Tobira Therapeutics Inc Earnings Release - After Market Close (NASDAQ:TBRA)
biz.yahoo.com - August 9 at 11:01 AM
sbwire.com logoInvestigation for Investors in Shares of Tobira Therapeutics Inc (NASDAQ:TBRA) over Possible Violations of Securities Laws (NASDAQ:TBRA)
www.sbwire.com - August 3 at 11:00 AM
finance.yahoo.com logoTobira Therapeutics to Present at the 36th Annual Canaccord Genuity Growth Conference (NASDAQ:TBRA)
finance.yahoo.com - August 2 at 10:58 AM
twst.com logoTobira Therapeutics Inc.: Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call (NASDAQ:TBRA)
www.twst.com - August 1 at 7:30 PM
publicnow.com logoTobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call (NASDAQ:TBRA)
www.publicnow.com - August 1 at 8:21 AM
News IconTobira Therapeutics, Inc. (NASDAQ:TBRA) Reveals CENTAUR Didn’t Meet Study Endpoint (NASDAQ:TBRA)
wallstreetpr.com - July 28 at 11:02 AM
investors.com logoTobira Therapeutics shares slump on phase II trial (NASDAQ:TBRA)
www.proactiveinvestors.com - July 26 at 11:10 AM
News IconTobira Therapeutics (TBRA) Sinks on Disappointing Liver Drug Trial (NASDAQ:TBRA)
www.economiccalendar.com - July 26 at 11:10 AM
rttnews.com logoTobira Therapeutics Inc. (TBRA) Plunged To A New Low On Phase 2 Study Results (NASDAQ:TBRA)
www.rttnews.com - July 26 at 11:10 AM
biz.yahoo.com logoTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:TBRA)
biz.yahoo.com - July 25 at 5:25 PM
bizjournals.com logoPeninsula biotech's stock tanks on poor trial results (NASDAQ:TBRA)
feeds.bizjournals.com - July 25 at 2:22 PM
marketwatch.com logoTobira Therapeutics' stock loses half its value after trial misses primary endpoint (NASDAQ:TBRA)
www.marketwatch.com - July 25 at 9:19 AM
publicnow.com logoTobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year (NASDAQ:TBRA)
www.publicnow.com - July 25 at 9:08 AM
finance.yahoo.com logoCoverage initiated on Tobira Therapeutics by Cantor Fitzgerald (NASDAQ:TBRA)
finance.yahoo.com - July 6 at 2:04 PM
News IconTobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH (NASDAQ:TBRA)
www.pharmiweb.com - July 1 at 7:43 PM
4-traders.com logoTobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH (NASDAQ:TBRA)
www.4-traders.com - June 27 at 7:37 PM
publicnow.com logoTobira's Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH (NASDAQ:TBRA)
www.publicnow.com - June 27 at 4:51 PM
4-traders.com logoTobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology (NASDAQ:TBRA)
www.4-traders.com - June 17 at 7:24 PM
publicnow.com logoTobira's Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology (NASDAQ:TBRA)
www.publicnow.com - June 16 at 4:59 PM
finance.yahoo.com logoTobira Therapeutics (TBRA) in Focus: Stock Up 6.4% in Session (NASDAQ:TBRA)
finance.yahoo.com - June 6 at 8:35 AM
nasdaq.com logoSum Up The Parts: Russell 2000 Has 12% Upside (NASDAQ:TBRA)
www.nasdaq.com - June 1 at 10:43 AM
publicnow.com logoTobira Therapeutics to Participate in Two Conferences in June (NASDAQ:TBRA)
www.publicnow.com - May 31 at 9:12 AM
finance.yahoo.com logoTOBIRA THERAPEUTICS, INC. Financials (NASDAQ:TBRA)
finance.yahoo.com - May 17 at 1:04 PM
publicnow.com logoTobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients (NASDAQ:TBRA)
www.publicnow.com - May 13 at 9:58 AM
publicnow.com logoTobira Therapeutics Reports First Quarter 2016 Financial and Business Results (NASDAQ:TBRA)
www.publicnow.com - May 9 at 4:18 PM
sg.finance.yahoo.com logoTobira reports 1Q loss (NASDAQ:TBRA)
sg.finance.yahoo.com - May 9 at 4:17 PM
biz.yahoo.com logoQ1 2016 Tobira Therapeutics Inc Earnings Release - After Market Close (NASDAQ:TBRA)
biz.yahoo.com - May 9 at 7:07 AM
publicnow.com logoTobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call (NASDAQ:TBRA)
www.publicnow.com - May 2 at 9:30 AM
publicnow.com logoTobira Announces Interim 12-week Results from the ORION Study (NASDAQ:TBRA)
www.publicnow.com - May 2 at 9:10 AM
publicnow.com logoTobira Announces Upcoming Presentations on Biomarkers for NASH at Two Scientific Meetings (NASDAQ:TBRA)
www.publicnow.com - April 21 at 4:21 PM
clintongazette.com logoTobira Therapeutics Incorporated (NASDAQ:TBRA) Sellers Increased By 12.37% Their Shorts - Clinton Financial (NASDAQ:TBRA)
www.clintongazette.com - March 27 at 2:58 PM
News IconTobira Therapeutics Inc Rises A lot Today, Is Now One of The Best Performer - RiversideGazette.com (NASDAQ:TBRA)
www.riversidegazette.com - March 23 at 2:48 PM
finance.yahoo.com logoTobira Therapeutics (TBRA) in Focus: Stock Up 5.4% in Session (NASDAQ:TBRA)
finance.yahoo.com - March 22 at 8:35 AM
News IconRevenue Update on Tobira Therapeutics Inc(NASDAQ:TBRA) - Street Edition (NASDAQ:TBRA)
www.streetedition.net - March 14 at 3:04 PM
News IconRecent Broker Updates On Tobira Therapeutics, Inc. (TBRA) - Risers & Fallers (NASDAQ:TBRA)
www.risersandfallers.com - March 10 at 2:42 PM
streetinsider.com logoTobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical Trials (NASDAQ:TBRA)
www.streetinsider.com - March 10 at 2:42 PM
streetinsider.com logoTobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical Trials - StreetInsider.com (NASDAQ:TBRA)
www.streetinsider.com - March 9 at 2:46 PM
finance.yahoo.com logoTobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials (NASDAQ:TBRA)
finance.yahoo.com - March 9 at 8:30 AM

Social

Tobira Therapeutics (NASDAQ:TBRA) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff